Apr 7 2010
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.
"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"
Poster presenter: Derrick Crook, M.D.
Saturday, April 10, 2010 3:30pm–4:30pm Central European Summer Time (6:30am-7:30am PST)
Presentation number: LB2401
"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"
Poster presenter: Mark A. Miller, M.D.
Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)
Presentation number: LB2394
Source:
Optimer Pharmaceuticals, Inc.
Combination therapy shows promising results in treating stage 3 melanoma